Medication info

Linagliptin Metformin Duo Tablet 2.5/1000 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Guju Pharmaceutical Co., Ltd.
Appearance
Light pink, oval, biconvex, film-coated tablet
Packaging
60 tablets/TP[10 tablets/TP x 6]
Approval status
Expired

MFDS item code 202002225 · Approved 2020.03.31

This product's status changed to Expired on 2025.03.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no history of prior diabetes drug treatment in whom adequate glycemic control cannot be achieved with monotherapy, the initial dose of this drug is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose of this drug should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at their current doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). 5. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). No studies have evaluated the safety and efficacy of switching to this drug in patients previously treated with another oral antihyperglycemic drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug, since the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug must not be administered to patients with hepatic impairment due to its metformin component. (See Precautions for Use, 1. Do not administer to the following patients).

Ingredients

Manufacturer
Guju Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This medication is used to help control blood sugar in adults with type 2 diabetes. It is particularly administered as an adjunct when blood sugar control is difficult with diet and exercise alone. It is effective for patients who have not previously received diabetic medication or for those who do not achieve adequate blood sugar control with monotherapy using metformin. Additionally, it can be used in combination with metformin, sulfonylureas, insulin, empagliflozin, etc., to improve blood sugar control. Various treatment methods can be administered according to the patient's condition, allowing for appropriate use. This effectively improves blood sugar control.

How to take

Adult dose

The dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This drug is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no history of prior diabetes drug treatment in whom adequate glycemic control cannot be achieved with monotherapy, the initial dose of this drug is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy: The initial dose of this drug should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this drug should start at their current doses of linagliptin and metformin. 4. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). 5. Patients unable to achieve adequate glycemic control with combination therapy of insulin and metformin: The initial dose of this drug should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this drug is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with caution in the following patients). No studies have evaluated the safety and efficacy of switching to this drug in patients previously treated with another oral antihyperglycemic drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug, since the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug must not be administered to patients with hepatic impairment due to its metformin component. (See Precautions for Use, 1. Do not administer to the following patients).

Precautions

This medication helps control blood sugar. However, it can cause serious side effects, such as lactic acidosis. Lactic acidosis can lead to a dangerous condition due to an excessive buildup of lactic acid in the body. This medication should not be administered to certain patients. For example, patients who are allergic to any of the components of this medication, those with type 1 diabetes, patients with severe renal impairment, patients with acute infections or severe dehydration, patients with liver dysfunction, women who are pregnant or breastfeeding should not take this medication. Moreover, this medication may cause hypoglycemia, so monitoring blood glucose levels is essential, especially when taken together with other blood sugar-lowering agents like insulin or sulfonylureas. Symptoms of hypoglycemia include dizziness, cold sweats, and severe fatigue. Patients with impaired renal function must undergo renal function tests before taking this medication and should not take it if their renal function is severely impaired. In situations where acute worsening of renal function is expected, the use of this medication should be temporarily suspended. Patients with heart disease or those with heart failure should undergo regular assessments of heart and kidney function while taking this medication. This medication must be temporarily discontinued before and after administration of iodine contrast agents used in radiological examinations, as well as for certain periods before and after surgery. If symptoms of acute pancreatitis or blistering similar to bullous pemphigoid appear during treatment, immediate consultation with a physician is required. Prolonged use of this medication may lead to decreased vitamin B12 levels; if vitamin B12 deficiency symptoms are suspected, blood tests should be conducted, and supplementation should be provided if necessary. It is advisable to avoid alcohol consumption while taking this medication, particularly during acute alcohol intoxication. Furthermore, there may be interactions with other medications, so it is vital to inform your doctor or pharmacist of any other medications you are taking. Women who are pregnant or planning to become pregnant should not take this medication, and breastfeeding women should also avoid it. This medication is not recommended for children under age 10, and dosage adjustments may be necessary for elderly patients depending on renal function. In case of overdose, gastrointestinal disorders or lactic acidosis may occur, and immediate medical treatment should be sought. Finally, this medication should be stored out of reach of children, in a cool, dry place.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • vitamin B12 deficiency and reduction
  • hypoglycemia
  • taste disorders
  • cough
  • decreased appetite
Show 143 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • bullous pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscal injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • anxiety
  • mood disorders
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • laceration
  • palpitations
  • dry eye
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • hematuria
  • hypotension
  • flushing
  • fatty liver
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • dizziness
  • sensory impairment
  • itching
  • hypertension
  • confusion
  • nocturia
  • dermatitis
  • hypercholesterolemia
  • increased blood creatinine
  • fever
  • facial swelling
  • hyperthermia
  • back pain
  • flank pain
  • osteoarthritis
  • limb pain
  • rotator cuff syndrome
  • diabetic neuropathy
  • headache
  • subdural effusion
  • corneal abrasion
  • falls
  • ligament sprain
  • upper limb fracture
  • speech impairment
  • epistaxis
  • vocal cord polyp
  • benign prostatic hyperplasia
  • angina
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • ligament sprain
  • myelodysplastic syndrome
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • stomatitis
  • increased serum triglycerides
  • anxiety
  • insomnia
  • depression

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to moisture; therefore, it should be stored in a tightly sealed container to prevent air or moisture from entering. It is recommended to maintain storage temperatures between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Light pink, oval, biconvex, film-coated tablet

Package unit

60 tablets/TP[10 tablets/TP x 6]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.